AbCellera Biologics Inc. (ABCL) Stock

AbCellera Biologics Inc. (ABCL) is a Healthcare stock trading at $5.54 (as of 2026-06-18), with a market capitalization of $1.75B and a trailing P/E of -11.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AbCellera Biologics Inc. provides an antibody discovery platform that uses computational methods to search and analyze natural immune system data to identify antibodies for potential therapeutic development. The company conducts multiple discovery programs with partners, including a research collaboration and license agreement with Eli Lilly, with 156 programs involving 36 partners as of Dec. 31, 2021.

Valuation — source: SEC EDGAR (first-party)
Price	$5.54
Market Cap	$1.75B
P/E Ratio	-11.5
EV / EBITDA	-8.3
Price / Book	1.80
Price / Sales	21.32
DCF Value (model)	$-9.27
DCF Upside vs Price	-267.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$75.13M
Net Margin	-194.9%
Return on Equity	-15.3%
Current Ratio	14.05
Revenue Growth (YoY)	160.6%
EPS Growth (YoY)	-10.9%
FCF Growth (YoY)	-6.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.67 (grey)

Valuation vs Sector & Industry
Stock P/E	-11.5
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-155.0%
vs Industry	-166.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BAKER BROS. ADVISORS LP ($105.66M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Carl Hansen
Employees	596
Country	CA
IPO Date	2021-03-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.